BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND ETV5, P41161, 2119, ENSG00000244405, ERM AND Prognosis
12 results:

  • 1. High levels of PD-L1 on platelets of NSCLC patients contributes to the pharmacological activity of Atezolizumab.
    Colarusso C; Falanga A; Terlizzi M; De Rosa I; Somma P; Sommella EM; Caponigro V; Panico L; Salviati E; Campiglia P; Salatiello G; Tramontano T; Maiolino P; Pinto A; Sorrentino R
    Biomed Pharmacother; 2023 Dec; 168():115709. PubMed ID: 37857253
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. etv5 transcriptionally activates TGFβ1 and promotes cancer cell invasion and migration of NSCLC.
    Li D; Shen Y; Ren H; Wang L; Yang J; Wang Y
    J Mol Histol; 2023 Oct; 54(5):419-426. PubMed ID: 37656259
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Clinicopathological Features and prognosis of Gastrointestinal Metastases From Breast Carcinoma: A Clinicopathological Study of 22 Patients.
    Wang S; Li W; Li S; Liu X; Zhang L; Hao C; Meng W; Zhao W; Tong Z
    Int J Surg Pathol; 2023 Sep; 31(6):1075-1084. PubMed ID: 36803140
    [No Abstract]    [Full Text] [Related]  

  • 4. Trends in the prescription of systemic anticancer therapy and mortality among patients with advanced non-small cell lung cancer: a real-world retrospective observational cohort study from the I-O optimise initiative.
    Snee M; Cheeseman S; Thompson M; Riaz M; Sopwith W; Lacoin L; Chaib C; Manley Daumont M; Penrod JR; O'Donnell JC; Hall G
    BMJ Open; 2021 May; 11(5):e043442. PubMed ID: 33941627
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Moesin as a prognostic indicator of lung adenocarcinoma improves prognosis by enhancing immune lymphocyte infiltration.
    Li YQ; Zheng Z; Liu QX; Lu X; Zhou D; Zhang J; Zheng H; Dai JG
    World J Surg Oncol; 2021 Apr; 19(1):109. PubMed ID: 33838692
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Prognostic significance of semi-quantitative FDG-PET parameters in stage I non-small cell lung cancer treated with carbon-ion radiotherapy.
    Shrestha S; Higuchi T; Shirai K; Tokue A; Shrestha S; Saitoh JI; Hirasawa H; Ohno T; Nakano T; Tsushima Y
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1220-1227. PubMed ID: 31758225
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. ETV4 overexpression promotes progression of non-small cell lung cancer by upregulating PXN and MMP1 transcriptionally.
    Wang Y; Ding X; Liu B; Li M; Chang Y; Shen H; Xie SM; Xing L; Li Y
    Mol Carcinog; 2020 Jan; 59(1):73-86. PubMed ID: 31670855
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Cytoplasmic expression of maspin predicts unfavourable prognosis in patients with squamous cell carcinoma of the lung.
    Matsuoka Y; Takagi Y; Nosaka K; Sakabe T; Haruki T; Araki K; Taniguchi Y; Shiomi T; Nakamura H; Umekita Y
    Histopathology; 2016 Jul; 69(1):114-20. PubMed ID: 27297724
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Ezrin Inhibition Up-regulates Stress Response Gene Expression.
    Çelik H; Bulut G; Han J; Graham GT; Minas TZ; Conn EJ; Hong SH; Pauly GT; Hayran M; Li X; Özdemirli M; Ayhan A; Rudek MA; Toretsky JA; Üren A
    J Biol Chem; 2016 Jun; 291(25):13257-70. PubMed ID: 27137931
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. A splicing variant of Merlin promotes metastasis in hepatocellular carcinoma.
    Luo ZL; Cheng SQ; Shi J; Zhang HL; Zhang CZ; Chen HY; Qiu BJ; Tang L; Hu CL; Wang HY; Li Z
    Nat Commun; 2015 Oct; 6():8457. PubMed ID: 26443326
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. PEA3 transcription factors are downstream effectors of Met signaling involved in migration and invasiveness of Met-addicted tumor cells.
    Kherrouche Z; Monte D; Werkmeister E; Stoven L; De Launoit Y; Cortot AB; Tulasne D; Chotteau-Lelievre A
    Mol Oncol; 2015 Nov; 9(9):1852-67. PubMed ID: 26238631
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.
    Pignochino Y; Grignani G; Cavalloni G; Motta M; Tapparo M; Bruno S; Bottos A; Gammaitoni L; Migliardi G; Camussi G; Alberghini M; Torchio B; Ferrari S; Bussolino F; Fagioli F; Picci P; Aglietta M
    Mol Cancer; 2009 Dec; 8():118. PubMed ID: 20003259
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.